Search

everythinglearnresearchcommunity

for

Search:↓

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

AHR ligands could treat inflammatory skin diseases.

Euph E and Euri A from Euphorbia neriifolia help control inflammation and immune response in cells.

Extracellular vesicles show promise for treating diseases but face challenges in development and regulation.

Ritlecitinib can help about 14,000 people with severe hair loss.

Erythrocyte-anchored nanoparticles improved Cepharanthine delivery and effectiveness for treating acute lung injury.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Ion sequential therapy improves heart function after a heart attack.

Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.

Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.

RCS-01 therapy is safe and may improve skin structure by affecting gene expression.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

The new assay can help develop products for hair re-growth.

Microneedles can precisely deliver cancer treatments with fewer side effects.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

Targeting amphiregulin may improve treatment for fibrosis and cancer.

New retinoids are effective for various skin conditions and are being developed to have fewer side effects.